Michail Ignatiadis, Director, Breast Medical Oncology Clinic and Program at Institut Jules Bordet, shared on LinkedIn:
“A landmark step for multi-cancer early detection.
The NHS-Galleri trial, now published in NEJM, randomized 142,942 asymptomatic adults to annual Galleri testing plus standard screening or standard screening alone.
The study did not meet its primary endpoint, with no significant reduction in combined stage III – IV cancers across the three screening rounds.
However, stage IV cancer diagnoses were reduced by 14% overall, with larger reductions emerging during the second and third screening rounds.
These findings bring us closer to answering a fundamental question in cancer interception:
Can detecting a cancer signal in blood meaningfully shift disease away from incurable metastatic presentation?
This question is particularly timely as today’s FDA Advisory Committee considers Galleri and, specifically, whether the available evidence supports an ‘early detection’ claim and how that concept should be defined in clinical practice.
Congratulations to Charles Swanton , the GRAIL team, and all NHS-Galleri investigators for delivering the first large randomized evidence base for multi-cancer early detection and moving the field from promise toward clinical validation.”
Title: Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Authors: Peter Sasieni, Peter Johnson, Thomas Round, Jane Warwick, Helen Jones, Saoirse Dolly, Lennard Lee, Yujin Lee, Harpal Kumar, Wei Liang, Rebecca Smittenaar, Richard D. Neal, Charles Swanton
You can also read:
